A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535)

High-risk acute promyelocytic leukemia (APL) remains a therapeutic challenge, with higher associated rates of early mortality and relapse than standard-risk APL. All-trans retinoic acid (ATRA) plus arsenic trioxide (ATO) is a well-established treatment for patients with standard-risk APL, but it is...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Blood Adv
Autori principali: Lancet, Jeffrey E., Moseley, Anna B., Coutre, Steven E., DeAngelo, Daniel J., Othus, Megan, Tallman, Martin S., Litzow, Mark R., Komrokji, Rami S., Erba, Harry P., Appelbaum, Frederick R.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Hematology 2020
Soggetti:
Myeloid Neoplasia
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7189292/
https://ncbi.nlm.nih.gov/pubmed/32330241
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019001278
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi